Red Flags Detected
- Going Concern (new) — Auditor now expresses substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash runway.
Skye Bioscience reports Phase 2a miss, pivots to combination therapy as cash runs out Q4 2026
Filed March 10, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~2 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade SKYE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 5, 2026 5:18 AM